ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).
Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
2017 may become a very exciting year for Patricia Biasutto, sepofarsen captain. Her work, developing a novel RNA therapy for Leber congenital amaurosis 10, has progressed steadily. The team expects to start a first clinical trial this year.
… into mid-2026 following Eli Lilly milestone related to partnership expansion Virtual R&D event today at 10:00 am … as well as research related to ongoing discovery efforts. Partnerships: ProQR will continue to execute on its existing … with Lilly. Additionally, ProQR may selectively form new partnerships, which could include multi-target discovery …
… milestones achieved in H1 related to progress in the Lilly partnership €96.2 million cash position as of end of Q2 … mid-2026, plus additional potential milestones from Lilly partnership LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 08, … first half of the year. With the benefits of a productive partnership, a differentiated pipeline strategy rooted in …
